国际免疫评分共识在III期结肠癌中的预后与化疗预测价值
国际免疫治疗学会多中心研究评估预设共识免疫评分在763例III期结肠癌患者中的预后价值及其与化疗对复发时间(TTR)的关联。高免疫评分患者复发风险最低,3年无复发率在高、中、低评分组分别为76.4%、65.9%、56.9%,高评分与TTR、OS、DFS延长显著相关,且独立于性别、T分期、N分期、侧别及微卫星状态。化疗仅在高免疫评分组与生存显著相关。
要点
- 高免疫评分与III期结肠癌TTR、OS、DFS延长显著相关,且独立于临床病理特征。
- 化疗与高免疫评分组生存显著相关,低免疫评分组无显著关联。
- 免疫评分在MSS患者中同样与TTR延长显著相关。
核心结论
- 高免疫评分与III期结肠癌生存延长显著相关,高评分患者从化疗中获益最大。
研究设计与样本
- 国际免疫治疗学会多中心研究,纳入763例AJCC/UICC TNM III期结肠癌患者,来自队列1(加拿大/美国)和队列2(欧洲/亚洲)。
- 通过数字病理量化肿瘤及浸润边缘CD3+和细胞毒性CD8+ T淋巴细胞密度,评估预设共识免疫评分。
- 主要终点为TTR,次要终点为OS、DFS、MSS状态下的预后及化疗疗效预测价值。
主要发现
- 高免疫评分患者复发风险最低,两个队列均一致。
临床怎么用
- 免疫评分可用于III期结肠癌预后分层,高评分患者复发风险更低。
- 高免疫评分患者可能从化疗中获益更多,低评分患者化疗获益不显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to evaluate the prognostic value of Immunoscore in patients with stage III colon cancer (CC) and to analyze its association with the effect of chemotherapy on time to recurrence (TTR). METHODS: An international study led by the Society for Immunotherapy of Cancer evaluated the predefined consensus Immunoscore in 763 patients with American Joint Committee on Cancer/Union for International Cancer Control TNM stage III CC from cohort 1 (Canada/United States) and cohort 2 (Europe/Asia). CD3+ and cytotoxic CD8+ T lymphocyte densities were quantified in the tumor and invasive margin by digital pathology. The primary end point was TTR. Secondary end points were overall survival (OS), disease-free survival (DFS), prognosis in microsatellite stable (MSS) status, and predictive value of efficacy of chemotherapy. RESULTS: Patients with a high Immunoscore presented with the lowest risk of recurrence, in both cohorts. Recurrence-free rates at 3 years were 56.9% (95% CI, 50.3% to 64.4%), 65.9% (95% CI, 60.8% to 71.4%), and 76.4% (95% CI, 69.3% to 84.3%) in patients with low, intermediate, and high immunoscores, respectively (hazard ratio [HR; high v low], 0.48; 95% CI, 0.32 to 0.71; P = .0003). Patients with high Immunoscore showed significant association with prolonged TTR, OS, and DFS (all P < .001). In Cox multivariable analysis stratified by participating center, Immunoscore association with TTR was independent (HR [high v low], 0.41; 95% CI, 0.25 to 0.67; P = .0003) of patient's sex, T stage, N stage, sidedness, and microsatellite instability status. Significant association of a high Immunoscore with prolonged TTR was also found among MSS patients (HR [high v low], 0.36; 95% CI, 0.21 to 0.62; P = .0003). Immunoscore had the strongest contribution χ2 proportion for influencing survival (TTR and OS). Chemotherapy was significantly associated with survival in the high-Immunoscore group for both low-risk (HR [chemotherapy v no chemotherapy], 0.42; 95% CI, 0.25 to 0.71; P = .0011) and high-risk (HR [chemotherapy v no chemotherapy], 0.5; 95% CI, 0.33 to 0.77; P = .0015) patients, in contrast to the low-Immunoscore group (P > .12). CONCLUSION: This study shows that a high Immunoscore significantly associated with prolonged survival in stage III CC. Our findings suggest that patients with a high Immunoscore will benefit the most from chemotherapy in terms of recurrence risk.
引用
- Mlecnik B, Bifulco C, Bindea G, et al. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. J Clin Oncol. 2020. PMID: 32897827. doi:10.1200/JCO.19.03205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。